Article

Expression of the Prostate Specific Membrane Antigen (PSMA) and Programmed Death-Ligand 1 (PD-L1) on Disseminated Tumor Cells from Early Triple Negative Breast Cancer Patients and their Clinical Impact

2025-07-24

Abstract excerpt

<title>Abstract</title> <p> Background Triple-negative breast cancer (TNBC) is the most aggressive breast cancer (BC) subtype, with a worse outcome, highlighting the need for novel biomarkers to treat patients accordingly. This study aimed to evaluate the presence of prostate-specific membrane antigen (PSMA) and programmed death-ligand 1 (PD-L1) on DTCs in the bone marrow of TNBC patients before and after neo-ad...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: aa242172-ce7c-5a4c-ae26-de8d3ca01229
DOI: 10.21203/rs.3.rs-6975457/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Expression of the Prostate Specific Membrane Antigen (PSMA) and Programmed Death-Ligand 1 (PD-L1) on Disseminated Tumor Cells from Early Triple Negative Breast Cancer Patients and their Clinical ImpactDOI 10.21203/rs.3.rs-6975457/v1Read

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read

The Correlation of PD-L1 Expression in Metaplastic BreastCancers with Clinical-Pathological Features and PrognosisSemantic proximity Read

Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohortSemantic proximity Read

Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer.Semantic proximity Read

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancerSemantic proximity Read

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic AdvancementsSemantic proximity Read

Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome DataSemantic proximity Read

The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.Semantic proximity Read

Characterization of the Immune Landscapes of Malignant Pleural Effusions and Their Corresponding Primary Tumors from Patients with Breast Carcinoma or Lung AdenocarcinomaSemantic proximity Read

Early Detection and Investigation of Extracellular Vesicles Biomarkers in Breast CancerSemantic proximity Read

MCT4 Upregulates PD-L1 Expression and Defines Novel Composite Therapeutic Targets for Triple-Negative Breast CancerSemantic proximity Read